Our Parkinson’s trial in the spotlight!
Our Parkinson’s trial in the spotlight! Thank you, Dr Ana Kriebs, for the elegant highlight in Nature Aging.
Our Parkinson’s trial in the spotlight! Thank you, Dr Ana Kriebs, for the elegant highlight in Nature Aging.
Our newest study published in npj assesses the incidence, prevalence and mortality of Parkinson’s disease (PD) in the entire Norwegian population – we find that the epidemiology of PD is highly dynamic, and changes as a function of both age and time period.
Encouraging results from our phase-I trial (NADPARK)! Oral nicotinamide riboside holds promise as a neuroprotective therapy for Parkinson’s disease.